Encourage Smoking Cessation and Offer Nicotine Replacement Therapy
The next step in preoperative management is to encourage smoking cessation and offer nicotine replacement therapy (Option 1). This patient is an active smoker scheduled for elective surgery, and smoking cessation represents the single most impactful intervention to reduce perioperative morbidity and mortality.
Why Smoking Cessation is the Priority
Multiple guidelines consistently emphasize that smoking cessation before surgery reduces critical perioperative complications:
- Smoking increases risk of pulmonary complications, surgical site infections, and poor wound healing in patients undergoing surgery 1
- Even smokers who quit just before surgery have fewer postoperative complications than those who continue smoking 2
- For patients with COPD specifically, smoking cessation is the only evidence-based intervention that improves prognosis by reducing exacerbations, ameliorating lung function decline, and improving quality of life 3
- In cardiac patients (relevant given her CAD), smoking cessation produces mortality reduction of greater magnitude than any other treatment or intervention 2
Optimal Approach to Smoking Cessation
Intensive counseling combined with nicotine replacement therapy is most effective 4:
- Counseling plus medication achieves significantly better cessation rates (OR 3.25) compared to no intervention 1
- Ideally, 4-8 weeks of preoperative abstinence reduces respiratory and wound-healing complications 4, 5
- However, even shorter periods of cessation provide benefit - one week of preoperative nonsmoking significantly predicts continued abstinence (OR 10.0) 2
- For elective procedures like hysterectomy, surgery timing can accommodate smoking cessation efforts without compromising oncologic or urgent surgical needs 1
Why the Other Options Are Incorrect
Preoperative stress test (Option 2): This patient has excellent functional capacity - she walks half a mile daily without difficulty. Current perioperative guidelines use functional capacity as a key risk stratification tool. Patients who can achieve ≥4 METs (metabolic equivalents) without symptoms are at low cardiac risk and do not require routine stress testing before noncardiac surgery. Walking half a mile demonstrates functional capacity well above this threshold.
Stopping beta blocker (Option 3): This is contraindicated. Atenolol should be continued perioperatively in this patient with established CAD and hypertension. Cardioselective beta-blockers are safe in COPD patients and should not be withheld 6, 7, 8. Abrupt perioperative discontinuation increases risk of cardiac events. The evidence shows cardioselective beta-blockers produce no adverse respiratory effects in COPD patients 7.
Preoperative corticosteroid burst (Option 4): There is no indication for this intervention. The patient is:
- Clinically stable (walking half a mile without difficulty)
- Already on optimal triple inhaler therapy (fluticasone-umeclidinium-vilanterol)
- Not experiencing an acute exacerbation (only mild wheezing on exam)
- Saturating adequately at 93% on room air
Prophylactic corticosteroid bursts are not recommended for stable COPD patients undergoing elective surgery.
Clinical Pearls
- Document the smoking cessation intervention in the medical record, as this counseling is a Class I recommendation for all surgical patients who smoke
- Refer to smoking cessation resources (quitlines, behavioral counseling) in addition to pharmacotherapy
- The patient's existing triple inhaler therapy should be continued perioperatively without modification 9
- Her cardioselective beta-blocker (atenolol) provides cardiovascular protection and does not worsen COPD 6, 7, 8